2-Acetyl-1,3-Cyclopentanedione for the Treatment of Metabolic Disorders
- Technology Benefits
- Prevents development of the diseaseDiminishes the pre-existing presence of the disease
- Technology Application
- Treatment of obesity. diabetes mellitus, metabolic syndrome, healthcare, pharmaceutical industires
- Detailed Technology Description
- Our inventors have successfully discovered 2-acetyl-1,3-cyclopentanedione (ACDP); ACPD has the potential to completely prevent development of, or reverse or diminish the pre-existing presence of, the diseases aforementioned. The technology is a novel, highly specific, potent, small molecular weight inhibitor of both atypical PKCs, PKC-zeta and PKC-lambda/iota. Effective treatment by a single agent for these abnormalities is promising for treating what is considered the major health concern of modern day; the obesity, metabolic syndrome, type 2 diabetes pandemic that constitute much of the cardiovascular disease.
- *Abstract
-
At the University of South Florida we have recently discovered that use of small molecular weight inhibitors of protein kinase C-zeta and protein kinase C-Lambda/Iota for treatment of obesity, the metabolic syndrome, diabetes mellitus, and related hypertriglyceridemia, hypercholesterolemia and hepatosteatosis.
- Country/Region
- USA
For more information, please click Here
